ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
about
ERCC1 and BRCA1 mRNA expression predicts the clinical outcome of non-small cell lung cancer receiving platinum-based chemotherapy.Xenograft assessment of predictive biomarkers for standard head and neck cancer therapiesPolymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance.Biomarkers to assess the efficiency of treatment with platinum-based drugs: what can metallomics add?The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.What's your poison? Impact of individual repair capacity on the outcomes of genotoxic therapies in cancer. Part II - information content and validity of biomarkers for individual repair capacity in the assessment of outcomes of anticancer therapy.Disruption of DNA repair in cancer cells by ubiquitination of a destabilising dimerization domain of nucleotide excision repair protein ERCC1.Cell cycle association and hypoxia regulation of excision repair cross complementation group 1 protein (ERCC1) in tumor cells of head and neck cancer.HPV-negative head and neck squamous cell carcinomas: how can we use the tumor protein signature?
P2860
Q33722508-F7DCA973-7B0E-455F-AC76-1B0021A0C5E4Q35602135-9CD4D6FB-A8FD-42BB-B4A5-27888029C9ECQ35632327-EFAB340D-79A1-4797-8B20-700E91C84656Q37722147-3E818582-5398-4FDB-B1A8-09643687A5CCQ38267182-5EFCBFAC-5DFD-4B04-B857-495F30DC0179Q38548142-0AAD6C87-7ADC-44BE-8452-FE53E8918D9FQ40735558-BD0E575A-B2D9-4CB2-B569-C72CADC4A51AQ41549007-5A29538D-B9EF-4BCC-9842-87766F57D896Q41782195-667BC2CD-5078-4B93-8C52-32551AAC6015Q51052868-9B1734C9-83EE-460E-8E27-B9ED625505EE
P2860
ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@en
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@nl
type
label
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@en
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@nl
prefLabel
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@en
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@nl
P2093
P2860
P356
P1476
ERCC1 is a prognostic biomarke ...... a randomised, phase II trial.
@en
P2093
J E Bauman
M C Austin
R G Martins
P2860
P2888
P304
P356
10.1038/BJC.2013.576
P407
P577
2013-09-24T00:00:00Z
P5875
P6179
1009168245